A battery including a housing; an electrolyte disposed in the housing; and a first electrode, wherein a porosity of the first electrode varies across a surface of the first electrode. A method includes obtaining a first electrode having a first predetermined porosity, obtaining a second electrode having a second predetermined porosity, wherein the second predetermined porosity is different than the first predetermined porosity, and laminating the first electrode with the second electrode, thereby to provide for an interface free electrode structure with a porosity gradient.
in vitroin vitro are provided. The methods include culturing a population of T cells with a population of antigen-loaded dendritic cells for at least about 28-48 days in a culture medium and isolating memory T cells (such as CD4+or CD8+ memory T cells) from the culture. Methods of treating a subject with cancer or infectious disease are also provided. The methods include administering to the subject memory T cells generated by the methods described herein, where the antigen-loaded dendritic cells are loaded with an antigen expressed by the cancer or the infectious agent causing the disease. Also provided are methods of identifying T cell receptors that specifically bind to an antigen recognized by a memory T cell, which include producing a population of memory T cells recognizing an antigen as described herein, and identifying the T cell receptor expressed by the memory T cells.
Embodiments perform multi-modal prediction of composite properties. A first mode input representing mechanical characteristic(s) of a composite sample is (i) transformed into material property definition(s) of physics-based model(s) or (ii) used to encode material property definition(s) in input variable(s) of a machine learning (ML) model. A second mode input representing morphological characteristic(s) of the sample is (i) transformed into phase volume parameter(s) of the physics-based model(s) or (ii) used to encode phase volume parameter(s) in the input variable(s) of the ML model. A third mode input associated with the sample is (i) transformed into electrical conductivity parameter(s) of the physics-based model(s) or (ii) used to encode electrical conductivity parameter(s) in the input variable(s) of the ML model. Using the physics-based model(s) or the ML model, property(ies) of the sample are predicted.
G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
G06F 30/23 - Design optimisation, verification or simulation using finite element methods [FEM] or finite difference methods [FDM]
A thin-film battery sensor includes a thin-film substrate; a common electrode, a second electrode, and a third electrode on the thin-film substrate; a first resistor on the thin-film substrate and coupled to the common electrode and the second electrode; and a second resistor on the thin-film substrate and coupled to the common electrode and the third electrode. A third resistor can be included that is coupled to the common electrode at one end and a corresponding electrode at another end. Each resistor is configured to function as a heater and/or thermistor to deposit heat onto the battery and detect local temperature variations. A readout integrated circuit (ROIC) is coupled to the sensor to apply a modulated current source and readout temperature modulation amplitude for determining thermal conductivity and thermal diffusivity tensors, which are used for estimation of state of health, state of charge, and state of safety of the battery.
G01R 31/396 - Acquisition or processing of data for testing or for monitoring individual cells or groups of cells within a battery
G01K 7/18 - Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat using resistive elements the element being a linear resistance, e.g. platinum resistance thermometer
G01K 13/00 - Thermometers specially adapted for specific purposes
G05D 23/24 - Control of temperature characterised by the use of electric means with sensing elements having variation of electric or magnetic properties with change of temperature the sensing element having a resistance varying with temperature, e.g. thermistor
H01M 10/617 - Types of temperature control for achieving uniformity or desired distribution of temperature
H01M 10/657 - Means for temperature control structurally associated with the cells by electric or electromagnetic means
The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.
This disclosure relates to a method of expressing the receptor-binding domain (RBD) region of the coronavirus SARS-CoV-2 Spike protein in a highly native form that is strongly reactive to natural antibodies induced upon SARS-CoV-2 infection or vaccination of humans and that more efficiently binds the angiotensin-converting enzyme 2 (ACE2) receptor. This method fuses the RBD to the C-terminus of an N-terminal fragment of the gp70 protein (the surface protein (SU) of the Friend57 strain of murine leukemia viruses). This method of expression enhances the native folding of the RBD and increases its recognition by antibodies present in immune sera and its ability to interact with the ACE2 receptor. Further disclosed are methods of using this form of RBD for various purposes.
The present application relates to single-domain antibodies and constructs comprising the single-domain antibodies, both of which exhibit affinity and specificity toward the CD16a activating receptor on natural killer cells and antigens on cancer cells, bacteria, parasites, or viruses.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
This disclosure provides novel animal models for use in studying lysosomal storage diseases and methods of treating lysosomal storage diseases by increasing a level or activity of TPP1.
2232232522 and/or ZnO. Also described herein are methods of making such glass-ceramics and articles suitable as a cover glass for an electronic device.
C03C 10/00 - Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition
11.
TECHNIQUES TO AUTOMATICALLY DETECT PAIN OR PAIN SENSITIVITY IN A SUBJECT
Techniques for measuring pain sensitivity in a subject include collecting from a sensor configured to measure a subject, while the subject is in a resting state, first nervous system signals such as inter-beat interval (IBI) data, facial muscle sub-second movement data, and non-facial muscle sub-second movement data. A Gamma function scale and shape parameter value pair is determined for micropeak statistics within the nervous system signals for the subject. The subject is determined to have a high sensitivity to pain when a scale value of the Gamma function scale and shape parameter value pair for the subject is below a threshold scale value that is based on a range of scale values determined for a population of individuals.
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Injury to a bodily lumen, such as a ureter, during a surgical procedure is prevented by tracking the locations of surgical instruments relative to the location of the bodily lumen. Image data that depict the bodily lumen are received. A marker instrument is introduced into the bodily lumen. The marker instrument has fluorescent and non-fluorescent markers, where a geometry of each non-fluorescent marker is known. Based on the image data, the location of the bodily lumen is determined from measured fluorescence signals of the fluorescent markers and a position of the marker instrument is determined by calculating a distance between the non-fluorescent markers and the imaging system. A location of a second surgical instrument relative to the first surgical instrument is then determined based on a calculated separation distance between the position of the first surgical instrument and a position of the second surgical instrument. Surgical navigation data are generated and output with the computer system. The surgical navigation data may be generated at least in part based on the calculated separation distance.
Methods and compositions for the treatment of cancer are disclosed herein. More specifically, disclosed herein are methods and compositions for the treatment of KRASi resistant cancers using NFAT5 inhibitors.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
The present disclosure provides novel mica and graphene-reinforced polymer matrix composites and methods for producing them. The disclosed composition shows improvements in mechanical properties, such as stiffness, tensile strength, and impact energy absorption compared to conventional polymers and exhibits lower electrical conductivity compared to carbon material-based reinforced polymer composites.
C04B 35/52 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbon, e.g. graphite
C04B 35/524 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbon, e.g. graphite obtained from polymer precursors, e.g. glass-like carbon material
Provided are biodegradable 3D porous hybrid protein (3D-PHP) nanoscaffolds that comprise MnO2 nanosheets and avoid covalent modification of proteins. These nanoscaffolds demonstrate inflammatory stimuli-responsive drug release as well as disc-mimetic stiffness. Also provided are methods of using (e.g., treating intervertebral disc disease (IVDD)) and manufacturing such nanoscaffolds.
Cornus nuttallii), that is clearly distinguished by its floriferous display of large, bright-white floral bracts, attractive dark-green foliage, and tolerance of the incitants of powdery mildew.
Methods of expressing a heterologous nucleic acid in neural stem and progenitor cells (NSPCs), comprising transducing NPSCs with an adeno-associated virus 6 (AAV6) vector comprising the heterologous nucleic acid are provided. Methods of treating a neurological disorder in a mammalian subject, comprising administering to the subject a therapeutically effective amount of an adeno-associated virus 6 (AAV6) vector comprising a heterologous nucleic acid molecule, such as Gsx1, are also provided.
The invention provides a compound of formula (I):
The invention provides a compound of formula (I):
The invention provides a compound of formula (I):
or a salt thereof, R1-R4, X, L, and ring A have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of papain-like protease and as antiviral agents.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
19.
ACCELERATING MICROARCHITECTURE SIMULATION WITH MACHINE LEARNING
Methods and systems simulating a hardware design is disclosed, A plurality of microarchitecture agnostic trace data from a hardware design are extracted, The plurality of microarchitecture agnostic data is provided to a trained deep learning model, A simulation of microarchitecture corresponding to hardware information is commenced, A plurality of similarities or relationships between instruction features of the plurality of microarchitecture agnostic trace data is processed. A plurality of instruction embeddings are generated using a plurality of embedding layers from the trained deep learning model. A plurality of performance metric predictions associated with microarchitecture agnostic trace information outputted from the trained deep learning model is obtained. Is it determined whether a microarchitecture design modeled by the trained deep learning model meets a plurality of user-defined requirements.
Methods and systems are provided for performing classification using a structured, explainable classification model. The methods and systems may utilize knowledge anchor embeddings (or concept tokens) based on representations of human interpretable criteria derived from textual domain knowledge. Methods and systems for developing such models are also disclosed.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
21.
Flame Synthesis of Carbon-Based Films on Liquid Surfaces
Methods for the production of films, particularly carbon-based films, based on gas-phase deposition on a liquid surface, and the products fabricated by the methods are provided.
A battery includes a positive current collector; a positive electrode; an electrolyte; wherein the electrolyte comprises a solvent, wherein the solvent comprises at least one of fluorinated organosilicon and lithium metal; and a metal current collector, wherein the metal current collector comprises a lithium plated on the metal current collector, wherein a layer is coated over a lithium plated metal current collector, wherein the layer comprises at least nitrogen and fluorine.
This disclosure is based, at least in part, on unexpected discoveries that a novel composition of a leukotoxin (LtxA) polypeptide isolated from Aggregatibatier actin omycetcmcomitans can retain stability and biological activities for an extended period of time even after the composition, is subject to a process of lyophilization, storage, reconstitution, and/or further storage, or under an accelerated condition, and that a particular range of dosage of the LtxA polypeptide and administration regimen can provide high efficacy and low toxicity in treating cancer in a patient in need thereof.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
C07K 14/285 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
24.
TARGETED DELIVERY OF MRNA THERAPEUTICS TO LUNG PARENCHYMA USING ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (USA)
Inventor
Atochina-Vasserman, Elena
Weissman, Drew
Gow, Andrew
Abstract
The invention relates to methods of using lung targeted amphiphilic Janus dendrimers that form nanoparticles for delivery of therapeutic agents to the lung parenchyma.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
25.
SUBSTITUTED 2,3-DIHYDRO-4H-BENZO[E][ 1,3] OXAZIN-4-ONE COMPOUNDS AND METHODS OF USE THEREOF
AAR positive modulator compounds of Formula (I) and methods of use thereof for treating, ameliorating, and/or preventing anxiety, opiate-related disorder(s), alcohol-related disorder(s), benzodiazepine-related disorder(s), seizure or seizure disorder(s), and/or pain. In another aspect, the compounds of the disclosure are suitable for sedating a subject.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable software in the nature of a mobile application for analyzing educational test scores and data from others; Downloadable software in the nature of a mobile application for training educators in the field of bilingual education and early literacy; Downloadable software in the nature of a mobile application for performing assessments, surveys and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures; Downloadable computer software for analyzing educational test scores and data from others; Downloadable computer software for training educators in the field of bilingual education and early literacy; Downloadable computer software for performing assessments, surveys and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures; Recorded computer software for analyzing educational test scores and data from others; Recorded computer software for training educators in the field of bilingual education and early literacy; Recorded computer software for performing assessments, surveys and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures Analyzing educational tests scores and data for others; Standardized testing; Educational testing services; Arranging, conducting and organization of seminars, lecture presentations and symposiums for language training; Education services, namely, training educators in the field of bilingual education teaching and providing curricula in connection therewith; Educational services, namely, offering of assessments and surveys in the field of educator training and performance for the purpose of improving teaching procedures; Providing information and news in the field of teaching methodology and education; Education services, namely, training educators in the field of bilingual education and early literacy and providing curricula in connection therewith Software as a service (SAAS) services featuring software for analyzing educational test scores and data from others; Software as a service (SAAS) services featuring software for training educators in the field of bilingual education and early literacy; Software as a service (SAAS) services featuring software for performing assessments, surveys and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures; Providing on-line non-downloadable software for analyzing educational test scores and data from others; Providing on-line non-downloadable software for training educators in the field of bilingual education and early literacy; Providing on-line non-downloadable software for performing assessments, surveys, and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable software in the nature of a mobile application for analyzing educational test scores and data from others; Downloadable software in the nature of a mobile application for training educators in the field of bilingual education and early literacy; Downloadable software in the nature of a mobile application for performing assessments, surveys and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures; Downloadable computer software for analyzing educational test scores and data from others; Downloadable computer software for training educators in the field of bilingual education and early literacy; Downloadable computer software for performing assessments, surveys and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures; Recorded computer software for analyzing educational test scores and data from others; Recorded computer software for training educators in the field of bilingual education and early literacy; Recorded computer software for performing assessments, surveys and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures Analyzing educational tests scores and data for others; Standardized testing; Educational testing services; Arranging, conducting and organization of seminars, lecture presentations and symposiums for language training; Education services, namely, training educators in the field of bilingual education teaching and providing curricula in connection therewith; Educational services, namely, offering of assessments and surveys in the field of educator training and performance for the purpose of improving teaching procedures; Providing information and news in the field of teaching methodology and education; Education services, namely, training educators in the field of bilingual education and early literacy and providing curricula in connection therewith Software as a service (SAAS) services featuring software for analyzing educational test scores and data from others; Software as a service (SAAS) services featuring software for training educators in the field of bilingual education and early literacy; Software as a service (SAAS) services featuring software for performing assessments, surveys and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures; Providing on-line non-downloadable software for analyzing educational test scores and data from others; Providing on-line non-downloadable software for training educators in the field of bilingual education and early literacy; Providing on-line non-downloadable software for performing assessments, surveys, and observations in the field of educator training and performance for the purpose of improving bilingual education and early literacy teaching procedures
28.
GSK-3-BETA INHIBITOR-LOADED POLYMERIC SCAFFOLDS FOR THE TREATMENT OF MUSCLE INJURIES
Methods of repairing composite tissue injuries susceptible to adipocyte infiltration, by applying to the injury an electrospun polymer fiber scaffold comprising biocompatible and bioresorbable polymer fibers that are blended with an amount of a GSK-3 inhibitor that is effective to inhibit the infiltration of adipocytes into the scaffold and tissue. Polymer scaffolds blended with an amount of a GSK-3 inhibitor that is effective to inhibit the infiltration of adipocytes into the scaffold and tissue are also disclosed as are kits containing the scaffolds and stem cells for repairing tissue at the injury site.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
C12Q 1/6816 - Hybridisation assays characterised by the detection means
C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Techniques for automatically measuring cell type based on electrical impedance includes single cell type or population cell types. Imaging a single cell includes measuring impedance time series while a single cell traverses a gap between a pair of electrodes in a microfluidic channel. A virtual image of the single cell is generated using a trained neural network and the measured impedance time series. Each training instance includes impedance time series of a training instance cell and a microscopic image of the cell. Automatically determining cell type of a population includes measuring population impedance time series while multiple cells of a sample traverse the gap. A measured probability density function (PDF) of amplitudes of isolated extrema in the population is generated. A first cell type in the sample is determined automatically based on the measured PDF and a database storing a PDF for each cell type of multiple cell types.
In one aspect, the present disclosure relates to tumor cell targeting peptides. In another aspect, the present disclosure relates to a method of targeting a therapeutic composition to a tumor cell in a subject, the method comprising administering to the subject a composition comprising a tumor cell targeting peptide attached to and/or displayed on the surface of a solid particle or conjugated to a cytotoxic agent.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Self-limiting electrospray compositions including a non-charge-dissipative component and/or a charge-dissipative component. Self-limiting electrospray composition including a plurality of charge-dissipative components and excluding a non-charge-dissipative component. Methods for forming layers of self-limiting thickness. Methods for determining a conductivity of a material. Methods for repairing a flaw in a layer on a surface of an object.
B29C 64/188 - Processes of additive manufacturing involving additional operations performed on the added layers, e.g. smoothing, grinding or thickness control
B05B 5/025 - Discharge apparatus, e.g. electrostatic spray guns
B05D 1/04 - Processes for applying liquids or other fluent materials performed by spraying involving the use of an electrostatic field
B05D 5/00 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures
Cornus kousa that is clearly distinguished by its floriferous display of symmetrical dark pink colored floral bracts and attractive dark-green foliage.
This disclosure provides methods and systems for anomaly identification through privacy-enhanced two-step federated learning. This disclosure also provides methods and systems for training a classifier for anomaly identification through privacy-enhanced two-step federated learning.
The present invention relates to methods for low energy solvothermal vapor synthesis in an unsaturated vapor-phase reaction medium. By regulating the amount and pressure of carbon dioxide in the reaction medium, the product composition can be controlled.
Disclosed are variant-signaling primers for primer-dependent nucleic acid amplification methods. Also disclosed are multiplex assay methods, related reagent kits, and oligonucleotides for such methods.
ELECTROREDUCTION OF CARBON DIOXIDE (CO2) TO MULTI-CARBON PRODUCTS ON ELECTROCATALYST COMPRISED OF MOLYBDENUM DIPHOSPHIDE (M0P2) AND ITS DOPED DERIVATIVES
Phosphatidylserine (PS)-targeting biomolecules and related methods for impacting the function of memory T cells are provided. In the present methods, PS-binding biomolecules are delivered to peripheral blood mononuclear cells (PBMCs) or whole blood of a subject in the presence of antigens specific to one or more diseases, wherein the PBMCs or whole blood comprise memory T cells that are exhausted or non-responsive to the antigens specific to the one or more diseases. Delivery of the PS-binding biomolecules to the PBMCs or whole blood restores effector function in the antigen non-responsive memory T cells. The administration of PS-binding biomolecules to PBMCs or blood with T cell antigens specific to pathogens can also be used to develop ultrasensitive diagnostics for latent infections or memory T cells response induced by natural infection or vaccination.
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/06 - Antibacterial agents for tuberculosis
Methods of treating disease include measuring a CCR2 profile of a patent, selecting a CCR2 antagonist based on the CCR2 profile of the patient, and administering the CCR2 antagonist to the patient. Methods for stratifying one or more patients for pain medication based on a CCR2 profile include measuring a CCR2 profile of one or more patients and partitioning the one or more patients into predetermined groups or subgroups based on the CCR2 profile of the one or more patients. Kits for performing the methods are also described.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 40/10 - Cellular immunotherapy characterised by the cell type used
A61K 40/20 - Cellular immunotherapy characterised by the effect or the function of the cells
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
42.
CERMET WASTE FORMS FOR DISPOSAL OF WASTE FROM ADVANCED REACTORS
Systems, methods, and techniques disclosed and contemplated herein relate to processing high level radioactive waste (HLW). Exemplary techniques are applicable to various fuel types, such as metal/chloride salt HLW streams from pyroprocessing of sodium bonded metallic fast reactor fuel; metal and halide salt HLW from molten salt reactors; and SiC/pyrolytic carbon from mechanically breached TRISO (tri -structural isotropic particle fuel) kernels with oxide fission products (FPs) from reprocessing. Exemplary waste forms are cermets.
B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
C22C 1/051 - Making hard metals based on borides, carbides, nitrides, oxides or silicidesPreparation of the powder mixture used as the starting material therefor
C22C 1/053 - Making hard metals based on borides, carbides, nitrides, oxides or silicidesPreparation of the powder mixture used as the starting material therefor with in situ formation of hard compounds
C22C 29/12 - Alloys based on carbides, oxides, borides, nitrides or silicides, e.g. cermets, or other metal compounds, e. g. oxynitrides, sulfides based on oxides
Methods and systems for determining a disease state by obtaining a first plurality of nucleic acid sequences for genomic DNA from a sample from the gut of a subject. Determine, from the nucleic acid sequences a first plurality of genomic abundance values for a first plurality of gut bacteria and a second plurality of genomic abundance values for a second plurality of at least 20 species of gut bacteria. Apply a model to at least the first plurality of genomic abundance values and the second plurality of genomic abundance values, or one or more combinations thereof, thereby determining the disease state of the subject as an output of the model.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
A spiking neural network is provided, wherein each neuron of the spiking neural network includes a RC or RLC circuit formed of passive elements. The RC or RLC circuit provides a corresponding spiking function. In some cases, a portion of each neuron of the spiking neural network is implemented in a digital processor and further includes a digital to analog converter between the portion implemented in the digital processor and the RC or RLC circuit. In some cases, the spiking neural network is implemented as a fully analog neural network.
An embodiment provides a lightweight approach to real-time crowd pattern identification, and motion pattern determination using processes of existing video compression standards. An embodiment obtains a plurality of motion vectors, each motion vector indicating movement of a macroblock from a first frame of video data to a second frame of video data. Based on the plurality of motion vectors, a polygonal contour surrounding a subset of motion vectors from the plurality of motion vectors is determined, wherein the polygonal contour represents at least part of the group. A motion pattern of the group is identified based on the determined polygonal contour and the subset of motion vectors from the plurality of motion vectors.
H04N 19/176 - Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using adaptive coding characterised by the coding unit, i.e. the structural portion or semantic portion of the video signal being the object or the subject of the adaptive coding the unit being an image region, e.g. an object the region being a block, e.g. a macroblock
Disclosed is a concise, inexpensive and scalable method for preparing elastomers filled with conductive 2D nanoparticles. The method comprises independently filling elastomer polymer precursors and/or corresponding elastomer polymer curing agents or their precursors with conductive 2D nanoparticles by shear exfoliation of a layered material, followed by mixing the two components and curing to form the elastomer. Such filled elastomers have utility in preparing various types of sensors which are useful in a variety of practical applications and devices.
Disclosed herein are compounds useful for treating obstructive lung diseases. The compounds are TAS2Rs agonists and may further be used to treat disorders and conditions implicated by TAS2R. In some instances the disclosed compounds can be used to treat asthma.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
49.
CARDIAC ULTRASONIC FINGERPRINTING: AN APPROACH FOR HIGH-THROUGHPUT MYOCARDIAL FEATURE PHENOTYPING
A system for identifying cardiac injury is provided herein. The system includes at least one computing device and at least one application executable on the at least one computing device. The application causes the computing device to extract a plurality of radiomic features from an ultrasound scan associated with a patient, determine one or more myocardial characteristics by applying the extracted plurality of radiomic features to one or more phenotyping models, and identify a cardiac injury associated with the patient based at least in part on the one or more myocardial characteristics and matching the extracted plurality of radiomic features to a patient cluster.
Described are sulfinate salts and methods of using the same in synthesis. The sulfinate salt may be a salt of formula (I): wherein: a is 1 or 2; X+ais a cation having a +a charge; R121-41-41-4alkyl, F, or Cl; and R21-41-422; with the proviso that at least one of R1and R2 is not hydrogen.
C07C 303/02 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
C07C 303/22 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids by reactions not involving the formation of sulfo or halosulfonyl groups
C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
A composition is provided. The composition comprises a polyol part. The polyol part comprises a catalyst, a defoamer, and modified nanoparticles. The catalyst comprises at least one of a base catalyst, a metal catalyst, a quaternary ammonium catalyst, a phosphorus-based catalyst, or any combination thereof. The composition is an elastomeric polyurethane sealer.
A61K 6/831 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
52.
piRNA-BASED CONSTRUCTS FOR REGULATING GENE EXPRESSION AND METHODS OF USE THEREOF
This disclosure is based, in part, on the unexpected discovery that a piRNA-based construct is able to silence genes that are essential for transmission and/or infection of pathogens. The disclosed constructs and methods of use thereof capitalize on the role piRNAs play in transcriptional silencing and general immunity and enable development of transgenic approaches to inhibit transmission of human and crop diseases.
The present invention includes recombinant AAV vectors comprising an inducible transcriptional activator which is operably linked to a muscle-specific promoter, wherein the AAV vector further comprises a capsid gene specific for muscle tissue. The invention further includes methods of producing and using said recombinant AAV vectors to introduce transgenes into target cells and treat diseases in subjects in need thereof.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
54.
COMPOSITIONS AND METHODS FOR THE ISOLATION AND PURIFICATION OF ANTI-FUNGAL PROTEIN FROM EPICHLOE FESTUCAE AND USE THEREOF FOR REDUCING SYMPTOMS OF DOLLAR SPOT DISEASE IN TARGETED PLANT SPECIES
Foundry casting elements and methods of forming the same, the methods including: forming an aqueous slurry including an inorganic binder precursor, shaping the slurry using a pattern, curing the shaped slurry using a low temperature solidification process to form a casting element, and removing the pattern from the casting element.
B22C 1/12 - Compositions of refractory mould or core materialsGrain structures thereofChemical or physical features in the formation or manufacture of moulds characterised by additives for special purposes, e.g. indicators, breakdown additives for manufacturing permanent moulds or cores
B22C 1/14 - Compositions of refractory mould or core materialsGrain structures thereofChemical or physical features in the formation or manufacture of moulds characterised by additives for special purposes, e.g. indicators, breakdown additives for separating the pattern from the mould
B22C 1/16 - Compositions of refractory mould or core materialsGrain structures thereofChemical or physical features in the formation or manufacture of moulds characterised by the use of binding agentsMixtures of binding agents
B22C 1/18 - Compositions of refractory mould or core materialsGrain structures thereofChemical or physical features in the formation or manufacture of moulds characterised by the use of binding agentsMixtures of binding agents of inorganic agents
B22C 3/00 - Selection of compositions for coating the surfaces of moulds, cores, or patterns
B82B 1/00 - Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
57.
ANTIMICROBIAL COMPOSITION FOR INHIBITING MICROBIAL ORGANISMS IN ALLOGRAFT AND THE METHOD THEREOF
Methods for producing allograft tissue by applying an antimicrobial solution to allograft tissue. The antimicrobial solution exhibits antimicrobial activity to make allograft resistant to microbial organisms, such as bacterium. Surface-modified tissue grafts prepared by these methods are also disclosed.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
The present disclosure relates to a biomaterial matrix having a live bacteria impregnated hydrogel, using the biomaterial matrix to treat epidermal inflammation of an animal, and wearable electronic devices having the biomaterial matrix installed thereon.
Compositions and methods for the rapid and efficient production of transgenic soybean expressing heterologous proteins or RNAs of interest in seed, pod and root plastids are disclosed.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
62.
METHODS OF DIAGNOSING B CELL MALIGNANCIES, DETECTING B CELL MALIGNANCY RELAPSE, AND TREATING THEREOF
Embodiments described here are directed to novel methods for detecting commensal bacteria-specific antibodies, such as commensal bacteria-specific immunoglobulin antibodies, in a blood sample or tissue fluid from a subject suspected of or suffering from a B cell malignancy, where the methods are for early detection or diagnosis of B cell malignancies and for early detection of relapse or recurrence of a B cell malignancy in remission patients previously diagnosed as suffering from a B cell malignancy. Also, described are embodiments directed to apparatuses for use with the novel methods described here. Methods of treating a subject suspected of or suffering from a B cell malignancy or a relapse or a recurrence of a B cell malignancy that can be used in combination with or without the methods of detecting commensal bacteria-specific antibodies and/or standard of care treatment are also provided here.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
The disclosure provides compound of formula (I): or a salt thereof, wherein R'-R10, W, X, Y, and Z have any of the values described in the specification, as well as compositions comprising such compounds or salts, methods of making such compounds and salts, and methods of using such compounds and salts, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.
The invention provides compounds of formula (I):
The invention provides compounds of formula (I):
The invention provides compounds of formula (I):
wherein R1-R3, n, and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.
C07C 235/88 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having the nitrogen atom of at least one of the carboxamide groups further acylated
C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
66.
METHOD AND APPARATUS FOR ACHIEVING HIGH ELECTROSPRAY DEPOSITION EFFICIENCY ON LOW AREA TARGETS
A method, including: establishing an electric field (210) in an electrospray deposition device (100B) and within the electric field emitting a spray of a medium (114) comprising payload materials (116A) from an emitter (104) toward a conductive target (132) disposed on an insulated conductive body (200); disposing charged payload materials (116BE) on the insulated conductive body; and establishing field lines (130BE) in the electric field between the emitter and the charged payload materials on the insulated conductive body to stabilize the electric field and between the emitter and the target to carry the spray of the medium to the target.
Described herein are compounds, compositions, and methods for selectively targeting insulin receptor isoform A (IR-A). In some embodiments, the compounds, compositions, and methods comprise an antisense oligonucleotide (ASO) targeted to IR-A for treating or preventing diseases and conditions characterized by elevated IR-A expression. In some embodiments, the compounds, compositions, and methods selectively reduce an expression level of IR-A. In some embodiments, the ASO comprises a modified oligonucleotide comprising at least one modified internucleoside linkage and at least one modified sugar moiety. In some embodiments, the disease or condition comprises cancer, diabetes, or a combination thereof. Also described herein are compounds, compositions, and methods for inhibiting cancer cell growth or proliferation.
An anchorage system for prestressing a non-metallic (e.g., FRP) tendon against a support member may include a dead-end assembly and a live-end assembly configured to be placed on opposite sides of the support member, each assembly having a support sleeve affixed to a support plate. The anchorage system may also include a tensioning rod coupled to an end of the support sleeve of the live-end assembly that is remote from the respective support plate, and a removable support box extending around the support sleeve of the live-end assembly, the tensioning rod extending through an opening defined in the removable support box, the support box configured to be an abutment structure against which a jack may be placed. The anchorage system may also include one or more slotted shim plates interposed between the support plate of the live-end assembly and a first confronting surface of the support member.
Techniques for determining a condition of a subject includes recording auditory brain stem (ABS) electrical signal data in a subject in response to an auditory signal delivered to the subject. First data is determined, wherein the first data indicates a temporal latency for each vertex in a set of one or more vertices in the ABS electrical signal or a property of one or more micropeaks in a portion of the electrical signal away from the vertices, or some combination. Each vertex indicates a response from a different anatomical location from the cochlea to the auditory cortex of the subject. A condition of the subject is determined based on a distance of the temporal latency determined for each vertex, or the property of the micropeaks, or some combination, from a predetermined set of values for temporal latency or property of micropeaks in a population of control individuals.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
71.
COMPOSITIONS AND METHODS COMPRISING MODIFIED CHIMERIC ANTIGEN RECEPTOR (CAR) MACROPHAGES
Described herein are compositions and methods for treating various indications in a subject including, but not limited to, atherosclerosis, cardiovascular diseases, inflammation, chronic inflammatory diseases, wounds, and spinal cord injuries. In some embodiments, the compositions and methods comprise a modified macrophage or monocyte comprising surface-expressed CD47-targeted chimeric antigen receptor (CAR) proteins and lipid-based particles conjugated to a surface of the modified macrophage or monocyte, wherein the lipid-based particles comprise a β-cyclodextrin (β-CD). In some embodiments, the lipid-based particles comprise lipid nanoparticles (LNPs).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
72.
OXAMATE DERIVATIVES AND PRODRUGS TO PREVENT CAOX STONE FORMATION
This patent document discloses novel oxamaies that can act as potent inhibitors of calcium oxalate (CaOx) crystallization and new macrocyclic prodrugs that will offer improved lipophilicity, small size, lower polar surface area, and greatly reduced solvent accessible surface area, all properties known to impart better oral bioavailability. Also disclosed herein are methods of treating diseases associated with abnormal levels of calcium oxalate and its crystallization.
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
73.
SYSTEMS AND METHODS FOR TRAINING PHYSICS-INFORMED NEURAL NETWORK SURROGATE MODELS TO MODEL PHYSICAL PROBLEMS USING THE FINITE ELEMENT METHOD
Systems and methods for training physics-informed neural network (PINN) surrogate models to model physical problems are provided. The method may comprise coupling, using a processor, one or more convolutional neural networks (CNNs) with a finite element method (FEM). The coupling may comprise calculating, for a finite element mesh comprising a plurality of finite elements, an internal force vector, P, a force vector, F, and a tangent stiffness matrix, KT, using the FEM. Each finite element may comprise one or more finite element nodes. The coupling may further comprise applying a CNN to the finite element mesh to obtain a solution to a physical problem. The CNN may be trained on a loss function, and the loss function may incorporate the internal force vector, P, and the force vector, F.
Synthesis of multi-cation oxide utilizing recycled carbonate-containing material. Also provided is a method of capturing carbon dioxide and releasing it as needed.
Using a novel dependence on plasmid-mediated expression (DOPE) technology, conditional depletion of GrgA, a Chlamydia-specific protein, has been demonstrated to result in greatly reduced reticulate body (RB) proliferation rate and near complete lack of elementary body (EB) formation, thus disrupting the normal chlamydial developmental cycle. This conditional GrgA-deficient Chlamydia allows study of chlamydial growth and developmental regulation and can be used as the basis of an attenuated, maturation-defective but immunogenic bacteria for use as an avirulent vaccine against Chlamydia.
Research Foundation of the City University of New York (USA)
Rutgers, The State University of New Jersey (USA)
Universidad Nacional De San Martin (Argentina)
UNIVERSIDAD NACIONAL DE SAN MARTIN (Argentina)
Inventor
Choi, Junyong
Kim, Hee-Sook
Erben, Esteban
Hossain, Zakir
Mukherjee, Aditi
Sharma, Diya
Abstract
A composition of matter having a general structure of:
A composition of matter having a general structure of:
A composition of matter having a general structure of:
The composition selectively inhbits Replacement Proteins A1 (RPA1) of Trypanosoma brucei.
The present disclosure provides substituted imidazo[1,5-a]pyridine N-heterocyclic carbene (NHC) ligands, catalyst complexes thereof, and methods using same. The present disclosure further provides synthetic methods of preparing N-heterocyclic carbene ligands and catalyst complexes thereof.
The invention provides inhibitors of interferon regulatory factor 5 (IRF5) nuclear localization and methods of using the inhibitors to treat autoimmune diseases such as systemic lupus erythematosus (SLE).
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The invention provides methods and compositions that are useful for treating allergic diseases, bacterial infections, fungal infections, viral infections, mastocytosis, mast cell-mediated inflammation and parasite infections (e.g., helminth infections).
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The Board of Trustees of the Leland Stanford Junior University (USA)
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (USA)
YALE UNIVERSITY (USA)
Inventor
Pelechano Garcia, Vicente Jose
Barrett, Donal
Steinmetz, Lars M.
Javanmard, Mehdi
Tayyab, Muhammad
Scharfe, Curt
Griffin, Peter B.
Abstract
Provided herein is a method for detecting a target nucleic acid in a sample. In some embodiments, the method may comprise: (a) amplifying the target nucleic acid isothermally in the presence of one or more compaction oligonucleotides to produce a product that comprises condensed amplification products; (b) flowing the product through a microfluidic channel; and (c) detecting a change in impedance as the condensed amplification products pass through the microfluidic channel. A microfluidic system and kit for preforming the method are also provided.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
81.
NANOPARTICLES FOR DIRECT REGULATION OF MITOCHONDRIAL GENE EXPRESSION
Compositions comprising biologically active synthetic nanoparticle constructs and methods of use thereof to modify mitochondrial gene expression including transcriptional repression and transcriptional activation.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
82.
Nuclease-Independent Targeted Gene Editing Platform and Uses Thereof
A01N 37/02 - Saturated carboxylic acids or thio-analogues thereofDerivatives thereof
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
Methods of expanding a population of immune cells, such as natural killer cells or CAR-modified natural killer cells, using exosomes, and methods of producing the exosomes from a population of 721.221 cells transduced or transfected with a membrane-bound IL-21 (mIL-21) or a population of 721.22 cells transduced or transfected with a mIL-21 and B7-H6. Methods of treating a cancer or an infectious or immune disease, wherein immune cells expanded using the exosomes are administered to a subject with the cancer or the infectious or immune disease are also provided.
Disclosed herein are embodiments of compounds that exhibit Crk-like protein inhibition. The compound embodiments can be used to suppress or prevent tumor cell growth and/or to inhibit a Crk-mediated signaling pathway. Methods of making and using the compound embodiments are disclosed herein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/39 - Heterocyclic compounds having sulfur as a ring hetero atom having oxygen atoms in the same ring
A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
A robot arm having a series of rigid links including a first rigid link and a final rigid link, the links being operatively controlled via tendon-driven joints, each tendon-driven joint comprising a motorized spool configured to rotate in either of two directions and operatively coupled, via a cable assembly having an elastic portion, to a pulley configured to move a respective rigid link thereby. A controller adapts robot arm motion in response to position and force sensing signals. A tendon-driven joint may be implemented via one motor controlling the tension of two cables acting in opposing directions and coupled between respective ones of a pair of common-driven spools and a pair of pulleys.
Nanoparticle compositions and methods inhibiting amyloid beta (Aβ) fibrilization in a subject in need thereof using nanoparticles to target fibril β-amyloid (fAβ)-specific scavenger receptors. Also provided is a method of using nanoparticle compositions to treat Alzheimer's disease (AD) and similar amyloidopathies.
Methods and systems for predicting a subject's response to a therapy by obtaining a first plurality of nucleic acid sequences for genomic DNA from a sample from the gut of a subject. Determine, from the nucleic acid sequences, a plurality of genomic abundance values for a plurality of gut bacteria. Apply a model to the plurality of genomic abundance values, thereby obtaining the prediction of a subject's response to a therapy as an output of the model.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
A method for forming a scaffold for use in fabricating a soft tissue implant, comprising: receiving, by a processor, soft tissue data corresponding to dimensions for a soft tissue, and a first and second weighting factor selected based on the dimensions of the soft tissue; transforming, by the processor, the soft tissue data, based on the first and second weighting factors, into a plurality of pin coordinates in a multi-dimensional space defining a shape of the scaffold for use in fabricating the soft tissue implant; and providing, by the processor, instructions to form the scaffold using weaving operations based on the pin coordinates.
The disclosure provides, in various embodiments, antibodies and antigen binding fragments thereof, and polypeptides that bind tumor necrosis factor-alpha (TNF-α). The disclosure also provides, in various embodiments, polynucleotides encoding antibodies and antigen binding fragments thereof, and polypeptides; vectors and host cells suitable for expressing the antibodies and antigen binding fragments thereof, and polypeptides; and methods for treating TNF-α-associated diseases or conditions.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
94.
COMPUTER-IMPLEMENTED METHODS FOR QUANTUM MECHANICAL BINDING AFFINITY SCORING
RUTGERS, THE STATES UNIVERSITY OF NEW JERSEY (USA)
Inventor
Pavanello, Michele
Genova, Alessandro
Martinez Bernal, Jessica
Abstract
Provided herein are computer-implemented methods for scoring a binding affinity between molecular subsystems. The methods include representing an interaction structure of the molecular subsystems, calculating the molecular interactions between the molecular subsystems, and generating an interaction energy score between the molecular subsystems.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
A reared colony of larval superworms (Zophobas morio) experienced the swift and unexplained death of about 90% of its population. From dead larvae, a high-abundance virus was isolated and identified as a novel densovirus, Zophobas morio black wasting virus (ZmBWV), by means of cryo-electron microscopy. Strains of this virus were sequenced and an engineered vaccine virus sequence was developed. The black wasting disease was replicated in larvae by inoculation with pathogenic strains of ZmBWV. Larvae were inoculated with a non-pathogenic strain as prophylaxis and later challenged by inoculation with a pathogenic strain. The larvae that received a non-pathogenic strain were protected from later disease and death but the larvae that received a saline solution were not. The invention provides methods and vaccine products to inhibit morbidity and mortality of ZmBWWV in darkling beetle larvae.
A composition tor use in treating a dental implant. Tire composition comprises a porous biodegradable polymer scaffold and a dicalciurn phosphate dihydrate (DCPD) coating within pores of the scaffold.
Embodiments operate a plurality of autonomous agents in a real-world environment. In an embodiment, each of the plurality of autonomous agents determines if a communication condition is above or below a threshold. Responsive to determining the communication condition is above the threshold, each agent determines a real-world action in the environment based on a respective indication of properties of the environment and a coordination communication. Responsive to determining the communication condition is below the threshold, each agent determines a real-world action in the environment based on the respective indication of properties of the environment. In turn, each agent performs its determined real-world action in the environment.
This disclosure provides compositions and methods for eliciting a T-cell mediated response to a pathogen or a tumor cell. Also provided are T-cell vaccines, T-cell adjuvants, and methods for performing T-cell diagnostics.
This disclosure provides recombinase enzymes that enable isothermal amplification of DNA or RNA. Also provided are consumer-friendly diagnostic devices in which the isothermal amplification occurs and a sample is analyzed. In particular, the recombinase enzymes and described diagnostic devices are used to detect inter alia, infectious diseases or non-infectious disease.
A device for treating neonatal intraventricular hemorrhage or brain injury comprises at least one laser configured to emit laser energy directed to a fontanelle or unfused suture of a neonatal cranium. The device includes a control unit electronically coupled to the laser or array of lasers. The control unit is configured to determine at least one laser parameter, such as a wavelength, an irradiance intensity, a voltage intensity, a power output, a focus angle, a focus distance, a duration of emission, a mode of emission, and a pulse frequency. A method of treatment using the device is also disclosed.
